PMID- 27391842
OWN - NLM
STAT- MEDLINE
DCOM- 20170210
LR  - 20210109
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 11
IP  - 1
DP  - 2016 Jul 8
TI  - Expression of amphiregulin predicts poor outcome in patients with pancreatic 
      ductal adenocarcinoma.
PG  - 60
LID - 10.1186/s13000-016-0512-4 [doi]
LID - 60
AB  - BACKGROUND: The validation of novel diagnostic, prognostic and predictive 
      biomarkers in cancer is crucial for optimizing the choice and efficacy of 
      personalized therapies. The aim of this study was to determine the epidermal 
      growth factor receptor (EGFR), epidermal growth factor receptor variant III 
      (EGFRvIII) and amphiregulin (AREG) protein expression levels and to evaluate the 
      prognostic significance of EGFR, EGFRvIII and AREG in pancreatic ductal 
      adenocarcinoma (PDAC). METHODS: The EGFR, EGFRvIII and AREG protein levels in 
      PDAC (n = 92) were examined by using immunohistochemistry. The associations 
      between EGFRvIII expression, AREG expression, AREG/EGFR co-expression and 
      clinicopathological factors were assessed, the correlation between AREG and EGFR 
      expression was analyzed and the survival analyses were performed. RESULTS: Among 
      the lesions of PDAC, 12 (13 %) stained positive for EGFRvIII, 49 (53.3 %) stained 
      positive for AREG and 22(23.9 %) stained double positive for AREG/EGFR. The 
      relationships between each protein expression level and the clinicopathologic 
      factors were examined, only AREG/EGFR co-expression was significantly related to 
      tumor differentiation (P = 0.032). The correlation between AREG and EGFR 
      expression was statistically insignificant (P = 0.709). Univariate survival 
      analysis proved that high tumor-node-metastasis (TNM) stage, poor tumor 
      differentiation and AREG expression were significant poor prognostic factors for 
      disease-free survival (DFS) and overall survival (OS). By multivariate survival 
      analysis, tumor differentiation was an independent poor prognostic factor for DFS 
      (HR = 1.785, P < 0.05), whereas high TNM stage (HR = 2.25, P < 0.05), poor tumor 
      differentiation (HR = 2.125, P < 0.01), positive resection margins (HR = 1.84, 
      P < 0.05), and AREG expression (HR = 1.822, P < 0.05) were all independent poor 
      prognostic factors for OS. CONCLUSIONS: In conclusion, our data indicate that 
      AREG expression is an important prognostic biomarker in PDAC .
FAU - Wang, Li
AU  - Wang L
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100730, People's Republic of China.
FAU - Wu, Huanwen
AU  - Wu H
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100730, People's Republic of China.
FAU - Wang, Lili
AU  - Wang L
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100730, People's Republic of China.
FAU - Lu, Junliang
AU  - Lu J
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100730, People's Republic of China.
FAU - Duan, Huanli
AU  - Duan H
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100730, People's Republic of China.
FAU - Liu, Xuguang
AU  - Liu X
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100730, People's Republic of China.
FAU - Liang, Zhiyong
AU  - Liang Z
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, 100730, People's Republic of China. 
      liangzhiyong1220@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20160708
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (epidermal growth factor receptor VIII)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amphiregulin/*metabolism
MH  - Carcinoma, Pancreatic Ductal/*diagnosis/metabolism
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pancreas/metabolism
MH  - Pancreatic Neoplasms/*diagnosis/metabolism
MH  - Prognosis
PMC - PMC4938900
OTO - NOTNLM
OT  - AREG
OT  - EGFR
OT  - EGFRvIII
OT  - Pancreatic ductal adenocarcinoma
EDAT- 2016/07/09 06:00
MHDA- 2017/02/12 06:00
PMCR- 2016/07/08
CRDT- 2016/07/09 06:00
PHST- 2015/12/18 00:00 [received]
PHST- 2016/07/02 00:00 [accepted]
PHST- 2016/07/09 06:00 [entrez]
PHST- 2016/07/09 06:00 [pubmed]
PHST- 2017/02/12 06:00 [medline]
PHST- 2016/07/08 00:00 [pmc-release]
AID - 10.1186/s13000-016-0512-4 [pii]
AID - 512 [pii]
AID - 10.1186/s13000-016-0512-4 [doi]
PST - epublish
SO  - Diagn Pathol. 2016 Jul 8;11(1):60. doi: 10.1186/s13000-016-0512-4.